Ceftriaxone Sodium

+ 20 more variants

• Biliary Pseudolithiasis (Sludge): Ceftriaxone can occasionally form a precipitate with calcium in the gallbladder, appearing as "sludge" on an ultrasound. This can cause symptoms similar to gallstones, such as upper abdominal pain, but it usually disappears once the drug is stopped.
• Pancreatitis: Inflammation of the pancreas has been reported rarely, possibly related to biliary obstruction.
• Phlebitis: Inflammation of the vein used for IV administration, which may cause redness and swelling along the vein.

> Warning: Stop taking Ceftriaxone and call your doctor immediately or seek emergency care if you experience any of the following:

1. 1Anaphylaxis (Severe Allergic Reaction): Symptoms include swelling of the face, lips, or tongue; difficulty breathing or swallowing; a rapid heartbeat; and a severe, widespread skin rash or hives.
2. 2Clostridioides difficile-Associated Diarrhea (CDAD): This is a severe infection of the colon. Symptoms include watery or bloody diarrhea (at least three times a day), severe stomach cramping, and fever. This can occur even weeks after the antibiotic treatment has ended.
3. 3Hemolytic Anemia: A condition where red blood cells are destroyed faster than the body can replace them. Symptoms include extreme fatigue, pale skin, dark-colored urine, and yellowing of the eyes (jaundice).
4. 4Seizures: Particularly in patients with pre-existing kidney disease who receive high doses of the medication.
5. 5Stevens-Johnson Syndrome (SJS): A rare, life-threatening skin reaction characterized by painful blisters and peeling of the skin and mucous membranes.

Prolonged or repeated use of Ceftriaxone may result in a "superinfection." This occurs when the antibiotic kills off the beneficial bacteria that normally keep other organisms in check, leading to an overgrowth of non-susceptible bacteria or fungi (such as oral thrush or vaginal yeast infections). Additionally, long-term use requires monitoring of the blood count to ensure the drug is not suppressing bone marrow function.

No FDA black box warnings are currently issued for Ceftriaxone. However, there is a prominent warning regarding its use in neonates. Specifically, Ceftriaxone must not be used in neonates (≤28 days old) if they are receiving calcium-containing IV fluids, due to the risk of fatal organ damage from calcium-ceftriaxone precipitates. This is considered a contraindication of the highest severity.

Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Your doctor may perform blood tests or imaging to monitor for these potential reactions.

For patients receiving prolonged courses of Ceftriaxone (e.g., more than 10 days), healthcare providers typically order the following tests:

• Complete Blood Count (CBC): To monitor for changes in white blood cells, red blood cells, and platelets.
• Liver Function Tests (LFTs): To ensure the drug is not causing biliary or hepatic stress.
• Renal Function Tests: To monitor kidney clearance, especially in patients with pre-existing renal disease.
• Prothrombin Time (PT/INR): To monitor for potential bleeding risks.

Ceftriaxone generally does not interfere with the ability to drive or operate machinery. However, some patients may experience dizziness or seizures as a rare side effect. If you feel lightheaded or unwell after receiving an injection, avoid driving until the feeling passes.

While Ceftriaxone does not typically cause a "disulfiram-like reaction" (nausea, vomiting, flushing) when consumed with alcohol—a reaction common with some other cephalosporins like cefotetan—it is generally advised to avoid alcohol while fighting a serious infection. Alcohol can dehydrate the body and weaken the immune system, potentially slowing recovery.

It is critical to complete the full course of Ceftriaxone as prescribed by your doctor. Stopping the medication too early, even if you feel better, can allow the remaining bacteria to continue growing. This can lead to a return of the infection and contributes to the development of antibiotic resistance, making future infections harder to treat.

> Important: Discuss all your medical conditions, including any history of gallbladder disease or kidney problems, with your healthcare provider before starting Ceftriaxone.

• Probenecid: Unlike many other cephalosporins, the renal clearance of Ceftriaxone is not significantly inhibited by probenecid. However, very high doses of probenecid might still slightly alter its excretion profile.
• Hormonal Contraceptives: Like many broad-spectrum antibiotics, Ceftriaxone may theoretically reduce the effectiveness of oral contraceptives by altering gut flora, which can decrease the reabsorption of estrogen. While the clinical evidence for this is limited, many providers recommend using a backup method of birth control (like condoms) during and for seven days after antibiotic therapy.

Because Ceftriaxone is administered by injection, there are no direct interactions with food intake that affect its absorption. However, maintaining adequate hydration and nutrition is essential for the body to fight the underlying infection.

• Vitamin K Supplements: High doses of Vitamin K may counteract the potential blood-thinning effects of Ceftriaxone, though this is rarely a clinical concern unless the patient is on anticoagulants.
• Probiotics: While not an "interaction" in the negative sense, taking probiotics (like Lactobacillus) may help prevent antibiotic-associated diarrhea. It is often recommended to take probiotics a few hours apart from the antibiotic dose to ensure the antibiotic doesn't kill the beneficial probiotic bacteria.

Ceftriaxone can interfere with certain medical tests, leading to false results:

• Urinary Glucose Tests: It may cause a false-positive result in tests using copper reduction methods (e.g., Benedict's solution or Clinitest). It does not affect glucose-oxidase-based tests (e.g., Diastix).
• Coombs' Test: Ceftriaxone can cause a false-positive result in the direct Coombs' test, which measures antibodies against red blood cells.
• Galactosemia Tests: It may produce false-positive results for galactosemia.

For each major interaction, the primary management strategy is clinical monitoring and laboratory testing. Always inform your doctor about all medications, including over-the-counter drugs and herbal supplements, before starting treatment.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to avoid dangerous interactions.

In these conditions, the use of Ceftriaxone requires a careful risk-benefit analysis by the healthcare provider:

• Penicillin Allergy: While not an absolute contraindication, patients with a history of mild penicillin allergy must be monitored closely for cross-sensitivity. If the previous reaction to penicillin was severe (anaphylaxis), Ceftriaxone should be used with extreme caution or avoided.
• History of Gastrointestinal Disease: Particularly colitis. The risk of developing C. difficile infection is higher in these patients.
• Gallbladder Disease: Because Ceftriaxone can cause biliary sludge, patients with pre-existing gallbladder issues may be at higher risk for symptomatic complications.

Patients should be aware of cross-sensitivity between Ceftriaxone and other beta-lactam antibiotics. This includes:

• Penicillins (e.g., Amoxicillin, Ampicillin)
• Other Cephalosporins (e.g., Cephalexin, Cefazolin, Cefdinir)
• Carbapenems (e.g., Meropenem, Imipenem)
• Monobactams (e.g., Aztreonam) - though cross-reactivity with aztreonam is generally very low.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug reactions, before prescribing Ceftriaxone to ensure your safety.

Clinical studies have not identified significant differences in safety or effectiveness between elderly patients and younger adults. However, because Ceftriaxone is partially excreted by the kidneys, and elderly patients are more likely to have decreased renal function, healthcare providers may monitor kidney function more closely. The risk of biliary sludge may also be slightly higher in older patients who are dehydrated or have other comorbid conditions.

In patients with renal impairment, the liver usually increases its clearance of Ceftriaxone to compensate. Therefore, no dosage adjustment is typically required for patients with kidney disease alone, as long as the dose does not exceed 2 grams per day. In patients with end-stage renal disease (ESRD), monitoring is recommended. Ceftriaxone is not removed by dialysis, so no supplemental doses are needed after a dialysis session.

For patients with liver disease, the kidneys typically compensate for the reduced biliary excretion. No dosage adjustment is usually necessary. However, in patients with both significant renal and hepatic impairment, the serum concentration of Ceftriaxone should be monitored, and the daily dose should not exceed 2 grams without close supervision.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding before starting this medication.

| Bioavailability | 100% (IM); N/A (Oral) |

| Protein Binding | 85% - 95% (Concentration-dependent) |

| Half-life | 6 to 9 hours (Adults) |

| Tmax | 2 to 3 hours (IM) |

| Metabolism | Minimal (Intestinal flora transform it to inactive metabolites) |

| Excretion | Renal 40-65%, Biliary/Fecal 35-60% |

• Molecular Formula: C18H18N8O7S3
• Molecular Weight: 554.58 g/mol (as free acid); 661.60 g/mol (as sodium salt hemiheptahydrate)
• Solubility: Highly soluble in water; sparingly soluble in methanol.
• Structure: It contains a beta-lactam ring fused to a dihydrothiazine ring, with a complex triazine side chain at the 3-position, which contributes to its long half-life and unique excretion properties.

Ceftriaxone is classified as a third-generation cephalosporin antibiotic. It belongs to the broader class of beta-lactam antibiotics. Related medications in the third-generation cephalosporin class include Cefotaxime, Ceftazidime, and Cefdinir. Compared to first-generation (e.g., Cefazolin) and second-generation (e.g., Cefuroxime) cephalosporins, Ceftriaxone has significantly better activity against Gram-negative bacteria and better penetration into the central nervous system.